Compare Abbott Laboratories (ABT) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Funko Inc — how do they compare? Abbott Laboratories trades at $110.94 (market cap $187.95B), while Funko Inc trades at $5.88 (market cap $332.33M). The key difference: Abbott Laboratories is far larger — about 565.6× Funko Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| ABT | FNKO | |
|---|---|---|
Market Cap | $187.95B | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $6.35 |
52-Week Low | $82.57 | $2.65 |
Enterprise Value | $214.96B | $552.98M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Funko (FNKO) trades at $6.19, up 5.27% with bullish technical signals and strong recent earnings beats. The company shows improving fundamentals with Q2 2026 revenue growth of 7% to $207.7 million and raised EBITDA guidance. Despite negative net margins, the stock trades at attractive valuation multiples with P/S of 0.35 and EV/EBITDA of 6.46. Recent management changes and successful product launches support positive momentum.
Outlook remains cautiously optimistic with analyst consensus leaning toward hold/buy. Key opportunities include continued execution of the 'Make Culture POP!' strategy and margin improvement, while risks include persistent negative profitability and competitive pressures in the collectibles market. The stock presents value potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
